Andrew Cittadine Monopar Therapeutics (MNPR) insider trading activity

Andrew Cittadine is Chief Operating Officer of Monopar Therapeutics. Currently has a direct ownership of 39,869 shares of MNPR, which is worth approximately $583,283. The most recent transaction as insider was on Sep 30, 2024, when has been sold 535 shares (Common Stock) at a price of $6.74 per share, resulting in proceeds of $3,605. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 39.9K

79.35% 3M change

13.17% 12M change

Total Value Held $583,283

Andrew Cittadine Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2024	SELL Payment of exercise price or tax liability	$3,605 $6.74 p/Share	535 Reduced 1.32%	39,869 Common Stock
Sep 30 2024	BUY Exercise of conversion of derivative security	-	1,791 Added 4.24%	40,404 Common Stock
Jun 30 2024	SELL Payment of exercise price or tax liability	$1,473 $0.73 p/Share	2,019 Reduced 1.03%	193,065 Common Stock
Jun 30 2024	BUY Exercise of conversion of derivative security	-	8,952 Added 4.39%	195,084 Common Stock
Jun 20 2024	BUY Open market or private purchase	$15,175 $0.74 p/Share	20,508 Added 9.92%	186,132 Common Stock
Jun 18 2024	BUY Open market or private purchase	$10,320 $0.86 p/Share	12,000 Added 6.76%	165,624 Common Stock
Jun 17 2024	BUY Open market or private purchase	$10,800 $0.9 p/Share	12,000 Added 7.25%	153,624 Common Stock
Jun 14 2024	BUY Open market or private purchase	$11,160 $0.93 p/Share	12,000 Added 7.81%	141,624 Common Stock
Jun 13 2024	BUY Open market or private purchase	$10,920 $0.91 p/Share	12,000 Added 8.47%	129,624 Common Stock
Jun 04 2024	BUY Open market or private purchase	$9,360 $0.78 p/Share	12,000 Added 9.26%	117,624 Common Stock
Jun 03 2024	BUY Open market or private purchase	$9,120 $0.76 p/Share	12,000 Added 10.2%	105,624 Common Stock
May 31 2024	BUY Open market or private purchase	$7,680 $0.64 p/Share	12,000 Added 11.36%	93,624 Common Stock
May 30 2024	BUY Open market or private purchase	$7,680 $0.64 p/Share	12,000 Added 12.82%	81,624 Common Stock
May 29 2024	BUY Open market or private purchase	$7,680 $0.64 p/Share	12,000 Added 14.7%	69,624 Common Stock
Mar 31 2024	SELL Payment of exercise price or tax liability	$2,106 $0.68 p/Share	3,098 Reduced 5.1%	57,624 Common Stock
Mar 31 2024	BUY Exercise of conversion of derivative security	-	8,952 Added 12.85%	60,722 Common Stock
Dec 31 2023	SELL Payment of exercise price or tax liability	$1,053 $0.34 p/Share	3,098 Reduced 5.65%	51,770 Common Stock
Dec 31 2023	BUY Exercise of conversion of derivative security	-	8,952 Added 14.03%	54,868 Common Stock
Sep 30 2023	SELL Payment of exercise price or tax liability	$1,626 $0.62 p/Share	2,624 Reduced 5.41%	45,916 Common Stock
Sep 30 2023	BUY Exercise of conversion of derivative security	-	8,953 Added 15.57%	48,540 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$3,489 $0.86 p/Share	4,057 Reduced 9.3%	39,587 Common Stock
Jun 30 2023	BUY Exercise of conversion of derivative security	-	13,841 Added 24.08%	43,644 Common Stock
Mar 31 2023	SELL Payment of exercise price or tax liability	$1,604 $1.39 p/Share	1,154 Reduced 3.73%	29,803 Common Stock
Mar 31 2023	BUY Exercise of conversion of derivative security	-	4,063 Added 11.6%	30,957 Common Stock
Dec 31 2022	SELL Payment of exercise price or tax liability	$3,332 $2.37 p/Share	1,406 Reduced 4.97%	26,894 Common Stock

Andrew Cittadine

Chief Operating Officer

Wilmette, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MNPR shares.

Notify only if

Value

Insider Trading

Get notified when an Monopar Therapeutics insider buys or sells MNPR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Monopar Therapeutics

Track Activities on MNPR

Account